Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Acrolein-mediated neuronal cell death and alpha-synuclein aggregation: Implications for Parkinson's disease.

Ambaw A, Zheng L, Tambe MA, Strathearn KE, Acosta G, Hubers SA, Liu F, Herr SA, Tang J, Truong A, Walls E, Pond A, Rochet JC, Shi R.

Mol Cell Neurosci. 2018 Apr;88:70-82. doi: 10.1016/j.mcn.2018.01.006. Epub 2018 Feb 3.

PMID:
29414104
2.

Neuroprotective effects of anthocyanin- and proanthocyanidin-rich extracts in cellular models of Parkinson׳s disease.

Strathearn KE, Yousef GG, Grace MH, Roy SL, Tambe MA, Ferruzzi MG, Wu QL, Simon JE, Lila MA, Rochet JC.

Brain Res. 2014 Mar 25;1555:60-77. doi: 10.1016/j.brainres.2014.01.047. Epub 2014 Feb 3.

3.

Cyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study.

Dumitriu A, Pacheco CD, Wilk JB, Strathearn KE, Latourelle JC, Goldwurm S, Pezzoli G, Rochet JC, Lindquist S, Myers RH.

Hum Mol Genet. 2011 Apr 15;20(8):1478-87. doi: 10.1093/hmg/ddr026. Epub 2011 Jan 21.

4.

Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models.

Su LJ, Auluck PK, Outeiro TF, Yeger-Lotem E, Kritzer JA, Tardiff DF, Strathearn KE, Liu F, Cao S, Hamamichi S, Hill KJ, Caldwell KA, Bell GW, Fraenkel E, Cooper AA, Caldwell GA, McCaffery JM, Rochet JC, Lindquist S.

Dis Model Mech. 2010 Mar-Apr;3(3-4):194-208. doi: 10.1242/dmm.004267. Epub 2009 Dec 28.

5.

Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity.

Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, Caldwell KA, Caldwell GA, Cooper AA, Rochet JC, Lindquist S.

Nat Genet. 2009 Mar;41(3):308-15. doi: 10.1038/ng.300. Epub 2009 Feb 1.

6.

The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis.

Gitler AD, Bevis BJ, Shorter J, Strathearn KE, Hamamichi S, Su LJ, Caldwell KA, Caldwell GA, Rochet JC, McCaffery JM, Barlowe C, Lindquist S.

Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):145-50. Epub 2007 Dec 27.

7.

Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.

Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG.

Science. 2007 Jul 27;317(5837):516-9. Epub 2007 Jun 21.

8.

Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation.

Outeiro TF, Klucken J, Strathearn KE, Liu F, Nguyen P, Rochet JC, Hyman BT, McLean PJ.

Biochem Biophys Res Commun. 2006 Dec 22;351(3):631-8. Epub 2006 Oct 26.

9.

Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models.

Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, Cao S, Caldwell KA, Caldwell GA, Marsischky G, Kolodner RD, Labaer J, Rochet JC, Bonini NM, Lindquist S.

Science. 2006 Jul 21;313(5785):324-8. Epub 2006 Jun 22.

Supplemental Content

Loading ...
Support Center